The nucleoside/nucleotide agents have the advantages of oral administration, excellent tolerance, use in advanced liver disease, and high potency in lowering serum HBV DNA levels. The
primary disadvantages of
these agents are the
need for long-term administration and
variable rates of antiviral drug resistance. Oral drugs with a high genetic barrier to resistance and/or high potency (eg, entecavir or tenofovir) are generally preferred to reduce the likelihood of resistance.